Similarly, several small molecule inhibitors of SPHK1/2 and S1PR have been shown to inhibit BC cell growth both in vitro and in vivo [75,76,77,78,79,80], of which FTY720 (fingolimod, an FDA-approved drug for multiple sclerosis), has been extensively studied. This evidence concerns the gene SPHK1 and breast cancer.